Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid

Blood

Volumn 88, Issue 11, 1996, Pages 4173-4182

  Rao, L Vijaya Mohan ^a   Hoang, An D ^b   Rapaport, Samuel I ^b  

^a Health Center at Tyler   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PROTHROMBIN; THROMBIN;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPOPROTHROMBINEMIA; IMMUNOBLOTTING; MONOLAYER CULTURE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; PROTEIN PURIFICATION; UMBILICAL VEIN;

EID: 0029959119     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.11.4173.4173     Document Type: Article

References (29)

1. Thiagarajan P, Shapiro SS, deMarco L: Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. J Clin Invest 66:397, 1980
2. Pengo V, Thiagarajan P, Shapiro SS, Heine MJ: Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 70:69, 1987
3. Loeliger A: Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh 3:237, 1959
4. Fleck RA, Rapaport SI, Rao LVM: Anti-prothrombin antibodies and the lupus anticoagulant. Blood 72:512, 1988
5. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA: Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66:629, 1991
6. Permpikul P, Rao LVM, Rapaport SI: Functional and binding studies of roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 83:2878, 1994
7. Rao LVM, Hoang AD, Rapaport SI: Differences in the interaction of lupus anticoagulant IgG with human prothrombin and bovine thrombin. Thromb Haemost 7093:668, 1995
8. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG: Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 74:1120, 1995
9. Oosting JD, Derksen RHW, Entjes HTI, Bouma BN, De Groot PG: Lupus anticoagulant activity is frequently dependent on the presence of β2 glycoprotein I. Thromb Haemost 67:499, 1992
10. Roubey RAS, Pratt CW, Buyon JP, Winfield JB: Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2 glycoprotein I. J Clin Invest 90:1100, 1992
11. Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM: Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68:297, 1992
12. Roubey RAS: Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 84:2854, 1994
13. Bajaj SP, Rapaport SI, Prodanos C: A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 11:397, 1981
14. Rao LVM, Robinson T, Hoang AD: Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: A kinetic study. Thromb Haemost 67:654, 1992
15. Forman SD, Nemerson Y: Membrane-dependent coagulation reaction is independent of the concentration of phospholipid-bound substrate: Fluid phase factor X regulates the extrinsic system. Proc Natl Acad Sci USA 83:4675, 1986
16. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680, 1970
17. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB: A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61:684, 1983
18. Bajaj SP, Rapaport SI, Barclay S, Herbst KD: Acquired hypoprothrombinemia due to nonneutralizing antibodies to prothrombin: Mechanism and management. Blood 65:1538, 1985
19. Peacock NW, Levine SP: Case report: The lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med Sci 307:346, 1994
20. Smirnov MD, Esmon CT: Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated Protein C. J Biol Chem 268:816, 1994
21. Staub HL, Harris EN, Khamashta MA, Savidge G. Chahade WH, Hughes GRV: Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 48:166, 1989
22. Karmochkine M, Cacoub P, Piette JC, Godeau P, Boffa MC: Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematous with thrombosis. Clin Exp Rheumatol 10:603, 1992
23. Sugi T, McIntyre JA: Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 86:3083, 1995
24. Rapaport SI, Ames SB, Duvall BJ: A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 15:212, 1960
25. Edson JR, Vogt JM, Hasegawa DK: Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 64:807, 1984
26. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, De Groot PG: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 81:2618, 1993
27. D'Angelo A, Crippa L, D'Angelo SV: Autoimmune protein S deficiency (the authors reply). N Engl J Med 328:1898, 1993
28. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT: On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 95:309, 1995
29. Malnick SDH, Sthoeger ZM: Autoimmune protein S deficiency. N Engl J Med 328:1898, 1993